Migalastat

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 158 publications

Long-Term Cardiac Remodeling During Migalastat Therapy in a Heterozygote Woman With Fabry Disease (N224S): A 9 Year Case Report.

Long-Term Cardiac Remodeling During Migalastat Therapy in a Heterozygote Woman With Fabry Disease (N224S): A 9 Year Case Report.

Journal: The American journal of case reports

Published: August 18, 2026

GLA is associated with ESCC progression and chemotherapy response via DNA damage repair-related pathways.

GLA is associated with ESCC progression and chemotherapy response via DNA damage repair-related pathways.

Journal: Frontiers in oncology

Published: June 05, 2026

Cardiovascular Drug Access in Australia and New Zealand: New PBS and PHARMAC Listings, 2023-2025.

Cardiovascular Drug Access in Australia and New Zealand: New PBS and PHARMAC Listings, 2023-2025.

Journal: Heart, lung & circulation

Published: April 27, 2026

Novel GLA variant in Fabry cardiomyopathy: evidence of pathogenicity and amenability to migalastat.

Novel GLA variant in Fabry cardiomyopathy: evidence of pathogenicity and amenability to migalastat.

Journal: Open heart

Published: January 30, 2026

Impact of migalastat therapy on corneal deposits in a female with Fabry disease: A case report.

Impact of migalastat therapy on corneal deposits in a female with Fabry disease: A case report.

Journal: Molecular genetics and metabolism reports

Published: January 23, 2026

Effectiveness and tolerability of migalastat in adult Fabry disease: A single regional centre experience.

Effectiveness and tolerability of migalastat in adult Fabry disease: A single regional centre experience.

Journal: Molecular genetics and metabolism reports

Published: November 01, 2025

Key considerations for measuring α-galactosidase A activity after long-term migalastat therapy-Avoiding in vitro inhibition effects.

Key considerations for measuring α-galactosidase A activity after long-term migalastat therapy-Avoiding in vitro inhibition effects.

Journal: Molecular genetics and metabolism reports

Published: October 30, 2025

Dapagliflozin in Patients With CKD With Fabry Disease.

Dapagliflozin in Patients With CKD With Fabry Disease.

Journal: Kidney international reports

Published: October 10, 2025

Impact of SGLT2 inhibitors in patients with Fabry disease.

Impact of SGLT2 inhibitors in patients with Fabry disease.

Journal: Clinical research in cardiology : official journal of the German Cardiac Society

Published: September 12, 2025

From Shoulder to Heart: Acute Shoulder Pain Leads to a Diagnosis of Fabry Disease.

From Shoulder to Heart: Acute Shoulder Pain Leads to a Diagnosis of Fabry Disease.

Journal: JACC. Case reports

Published: September 04, 2025

Treatment-related benefit and satisfaction in patients with Fabry disease in France: insight into patients' expectations and preferences from the prospective, non-interventional SATIS-Fab study.

Treatment-related benefit and satisfaction in patients with Fabry disease in France: insight into patients' expectations and preferences from the prospective, non-interventional SATIS-Fab study.

Journal: Orphanet journal of rare diseases

Published: July 21, 2025

Navigating Fabry Disease in a Military Aviator.

Navigating Fabry Disease in a Military Aviator.

Journal: Aerospace medicine and human performance

Published: July 11, 2025

Showing 1-12 of 158

Last Updated: 09/26/2026